Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in October 2019 on request of the Sponsor.
The sponsorship was transferred to Immune Design Ltd, United Kindom, in August 2016.
On 21 March 2016, orphan designation (EU/3/16/1634) was granted by the European Commission to Pharm Research Associates (UK) Limited, United Kingdom, for glucopyranosyl lipid A stable emulsion and recombinant New York oesophageal squamous cell carcinoma-1 protein (NY-ESO-1) for the treatment of soft tissue sarcoma.
EU/3/16/1634: Public summary of opinion on orphan designation: Glucopyranosyl lipid A stable emulsion and recombinant New York oesophageal squamous cell carcinoma-1 protein for the treatment of soft tissue sarcoma (PDF/147.53 KB)
First published: 02/05/2016
Last updated: 15/10/2019
Glucopyranosyl lipid A stable emulsion and recombinant New York oesophageal squamous cell carcinoma-1 protein
|Disease / condition||
Treatment of soft tissue sarcoma
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.